Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of IMT in Patients Undergoing Colon Resection
NCT06370884Phase 1Recruiting
- Sponsor
- University of Minnesota
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of biologically active human fecal material in diverticulitis, sigmoid colon cancer and Clostridioides difficile infection (CDI), sponsored by University of Minnesota. Primary endpoints: Safety of IMT at Day 180 and Comparison of fecal microbiota prior to and after IMT at Day 180. Started Feb 2024; status: recruiting.
02
Drugs
biologically active human fecal material
03
Conditions
diverticulitissigmoid colon cancerClostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06370884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370884.